Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C (anti-HCV antibodies and detectable HCV-RNA).~* Genotype 1b infection~* Treatment-naïve and non-cirrhotic~Exclusion Criteria:~* HCV genotype or subtype other than GT1b.~* Any current or past clinical evidence of cirrhosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spanish cohort with HCV treated with DAA (Type: None): Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).